Trial of Oral Valproic Acid for Retinitis Pigmentosa
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow
the progression of visual function loss and/or to restore visual function in patients with
Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability
information.
Phase:
Phase 2
Details
Lead Sponsor:
Foundation Fighting Blindness Foundation Fighting Blindness Clinical Research Institute